To Your Health: Company behind 'female Viagra' pill bought for $1 billion

Company behind ‘female Viagra’ pill bought for $1 billion

Ariana Eunjung Cha on well-being The 'breakthrough' drug Jimmy Carter is taking to treat his cancer By Brady Dennis The former president said he had received pembrolizumab, better known as Keytruda, which is among the first in a promising new class of drugs aimed at unleashing the human immune system to fight cancer.   Read full article » Working lots of overtime? Your risk of stroke may increase, study finds. By Ariana Eunjung Cha Researchers found that people working between 41 and 48 hours had a 10 percent higher risk of stroke. Those working 55 or more hours -- a scary 33 percent greater risk.  Read full article » Company behind ‘female Viagra’ pill bought for $1 billion By Brady Dennis Canadian drugmaker Valeant Pharmaceuticals has purchased Sprout, whose controversial drug flibanserin was approved by the FDA on Tuesday.  Read full article » Scientists are crediting the ALS Ice Bucket Challenge for breakthroughs in research By Robert Gebelhoff One year and $100 million later, dumping water on our heads seems to have made a difference.  Read full article »   The Post recommends: Lean & Fit Stay on top of the hottest fitness and healthy eating trends with this weekly newsletter. Sign me up   Shorter women have shorter pregnancies — and that can be a big problem By Brady Dennis Shorter mothers had shorter pregnancies, smaller babies and a higher risk for preterm births, a study shows.  Read full article » FDA warns makers of medical scopes in wake of deadly ‘superbug’ outbreaks By Brady Dennis The FDA issued warning letters to three of the largest manufacturers of duodenoscopes, which have been linked to outbreaks of a deadly superbug.  Read full article »        You received this e-mail because you signed up for the To Your Health newsletter. For additional free newsletters or to manage your newsletters, click here. We respect your privacy. If you believe that this e-mail has been sent to you in error, or you no longer wish to receive e-mail from The Washington Post, click here. Contact us for help. ©2015 The Washington Post  |  1150 15th St NW, Washington, DC 20071